File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Sensorineural hearing loss in patients treated for nasopharyngeal carcinoma: A prospective study of the effect of radiation and cisplatin treatment

TitleSensorineural hearing loss in patients treated for nasopharyngeal carcinoma: A prospective study of the effect of radiation and cisplatin treatment
Authors
KeywordsCisplatin
Nasopharyngeal carcinoma
Prognostic factors
Radiotherapy
Sensorineural hearing loss
Issue Date1996
PublisherElsevier Inc. The Journal's web site is located at http://www.elsevier.com/locate/ijrobp
Citation
International Journal of Radiation Oncology - Biology - Physics, 1996, v. 36 n. 2, p. 281-289 How to Cite?
AbstractPurpose: The pattern of sensorineural hearing loss (SNHL) after primary treatment for nasopharyngeal carcinoma (NPC) was studied, and the effect of cisplatin, radiotherapy dose, and fractionation were evaluated. Methods and Materials: One hundred thirty-two patients, 227 ears, and 1100 audiogram reports were analyzed. Radiotherapy dose ranged from 59.5 to 76.5 Gy. Fifty- two patients received preirradiation cisplatin, total dose 100-185 mg/m 2. Serial postirradiation bone conduction thresholds at 0.5 kHz, 1 kHz, 2 kHz, and 4 kHz were compared with pretreatment thresholds at respective frequencies. Increase of at least 15 dB was considered as significant and was further grouped as transient or persistent SNHL. Univariate and multivariate analyses were performed to identify predicting factors for persistent SNHL. Results: At median follow-up of 30 months, 24.2% of ears developed persistent SNHL. High frequency was more affected than low frequencies, 22 vs. 5.3%. Males were more affected than females, 29.4 vs. 15.5%, p = 0.0132. Incidence of persistent SNHL increased with age, with 0, 17.2, and 37.4% of patients aged under 30, between 30-50 and over 50 affected, respectively, p = 0.0001. High incidence was found in patient with postirradiation serous otitis media (SOM), 46.9%. Chemotherapy with cisplatin and radiation dose or fractionation had no significant effect. Multivariate analysis confirmed age, sex, and postirradiation SOM as significant prognostic factors for persistent SNHL. Conclusions: Transient and persistent SNHL occurred after radiotherapy, more commonly affecting high frequency. A low dose of preirradiation cisplatin did not increase the risk. A dose fractionation effect of radiotherapy was not confirmed in this study.
Persistent Identifierhttp://hdl.handle.net/10722/72005
ISSN
2023 Impact Factor: 6.4
2023 SCImago Journal Rankings: 1.992
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorKwong, DLWen_HK
dc.contributor.authorWei, WIen_HK
dc.contributor.authorSham, JSTen_HK
dc.contributor.authorHo, WKen_HK
dc.contributor.authorYuen, PWen_HK
dc.contributor.authorChua, DTTen_HK
dc.contributor.authorAu, DKKen_HK
dc.contributor.authorWu, PMen_HK
dc.contributor.authorChoy, DTKen_HK
dc.date.accessioned2010-09-06T06:37:24Z-
dc.date.available2010-09-06T06:37:24Z-
dc.date.issued1996en_HK
dc.identifier.citationInternational Journal of Radiation Oncology - Biology - Physics, 1996, v. 36 n. 2, p. 281-289en_HK
dc.identifier.issn0360-3016en_HK
dc.identifier.urihttp://hdl.handle.net/10722/72005-
dc.description.abstractPurpose: The pattern of sensorineural hearing loss (SNHL) after primary treatment for nasopharyngeal carcinoma (NPC) was studied, and the effect of cisplatin, radiotherapy dose, and fractionation were evaluated. Methods and Materials: One hundred thirty-two patients, 227 ears, and 1100 audiogram reports were analyzed. Radiotherapy dose ranged from 59.5 to 76.5 Gy. Fifty- two patients received preirradiation cisplatin, total dose 100-185 mg/m 2. Serial postirradiation bone conduction thresholds at 0.5 kHz, 1 kHz, 2 kHz, and 4 kHz were compared with pretreatment thresholds at respective frequencies. Increase of at least 15 dB was considered as significant and was further grouped as transient or persistent SNHL. Univariate and multivariate analyses were performed to identify predicting factors for persistent SNHL. Results: At median follow-up of 30 months, 24.2% of ears developed persistent SNHL. High frequency was more affected than low frequencies, 22 vs. 5.3%. Males were more affected than females, 29.4 vs. 15.5%, p = 0.0132. Incidence of persistent SNHL increased with age, with 0, 17.2, and 37.4% of patients aged under 30, between 30-50 and over 50 affected, respectively, p = 0.0001. High incidence was found in patient with postirradiation serous otitis media (SOM), 46.9%. Chemotherapy with cisplatin and radiation dose or fractionation had no significant effect. Multivariate analysis confirmed age, sex, and postirradiation SOM as significant prognostic factors for persistent SNHL. Conclusions: Transient and persistent SNHL occurred after radiotherapy, more commonly affecting high frequency. A low dose of preirradiation cisplatin did not increase the risk. A dose fractionation effect of radiotherapy was not confirmed in this study.en_HK
dc.languageengen_HK
dc.publisherElsevier Inc. The Journal's web site is located at http://www.elsevier.com/locate/ijrobpen_HK
dc.relation.ispartofInternational Journal of Radiation Oncology - Biology - Physicsen_HK
dc.rightsInternational Journal of Radiation: Oncology - Biology - Physics. Copyright © Elsevier Inc.en_HK
dc.subjectCisplatinen_HK
dc.subjectNasopharyngeal carcinomaen_HK
dc.subjectPrognostic factorsen_HK
dc.subjectRadiotherapyen_HK
dc.subjectSensorineural hearing lossen_HK
dc.subject.meshAdolescenten_HK
dc.subject.meshAdulten_HK
dc.subject.meshAgeden_HK
dc.subject.meshAntineoplastic Agents - adverse effectsen_HK
dc.subject.meshCisplatin - adverse effectsen_HK
dc.subject.meshCombined Modality Therapyen_HK
dc.subject.meshFemaleen_HK
dc.subject.meshHearing Loss, Sensorineural - etiology - physiopathologyen_HK
dc.subject.meshHumansen_HK
dc.subject.meshMaleen_HK
dc.subject.meshMiddle Ageden_HK
dc.subject.meshMultivariate Analysisen_HK
dc.subject.meshNasopharyngeal Neoplasms - drug therapy - radiotherapyen_HK
dc.subject.meshOtitis Media with Effusion - etiologyen_HK
dc.subject.meshProspective Studiesen_HK
dc.subject.meshRadiation-Sensitizing Agents - adverse effectsen_HK
dc.subject.meshSex Factorsen_HK
dc.titleSensorineural hearing loss in patients treated for nasopharyngeal carcinoma: A prospective study of the effect of radiation and cisplatin treatmenten_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0360-3016&volume=36&spage=281&epage=289&date=1996&atitle=Sensorineural+hearing+loss+in+patients+treated+for+nasopharyngeal+carcinoma:+a+prospective+study+of+the+effect+of+radiation+and+cisplatin+treatmenten_HK
dc.identifier.emailKwong, DLW: dlwkwong@hku.hken_HK
dc.identifier.emailWei, WI: hrmswwi@hku.hken_HK
dc.identifier.emailChua, DTT: dttchua@hkucc.hku.hken_HK
dc.identifier.emailAu, DKK: kinkwau@hkucc.hku.hken_HK
dc.identifier.authorityKwong, DLW=rp00414en_HK
dc.identifier.authorityWei, WI=rp00323en_HK
dc.identifier.authorityChua, DTT=rp00415en_HK
dc.identifier.authorityAu, DKK=rp00385en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/S0360-3016(96)00302-1en_HK
dc.identifier.pmid8892450-
dc.identifier.scopuseid_2-s2.0-0030250421en_HK
dc.identifier.hkuros13372en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0030250421&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume36en_HK
dc.identifier.issue2en_HK
dc.identifier.spage281en_HK
dc.identifier.epage289en_HK
dc.identifier.isiWOS:A1996VN74000002-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridKwong, DLW=15744231600en_HK
dc.identifier.scopusauthoridWei, WI=7403321552en_HK
dc.identifier.scopusauthoridSham, JST=24472255400en_HK
dc.identifier.scopusauthoridHo, WK=7402968844en_HK
dc.identifier.scopusauthoridYuen, PW=7103124007en_HK
dc.identifier.scopusauthoridChua, DTT=7006773480en_HK
dc.identifier.scopusauthoridAu, DKK=7004909224en_HK
dc.identifier.scopusauthoridWu, PM=8663653900en_HK
dc.identifier.scopusauthoridChoy, DTK=7102939127en_HK
dc.identifier.issnl0360-3016-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats